Login
$MREO
$0.30 -$0.00 (0.85%) After hours

$MREO 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI)

19 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a written notice (the “First Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) in...

11 Aug 2026 8-K: Results of Operations and Financial Condition

Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

11 Aug 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

14 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 14, 2026, Mereo BioPharma Group plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed. Of the ordinary shares entitled to vote, there were 436,766,255 ord...

12 May 2026 8-K: Completion of Acquisition or Disposition of Assets

London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026...

27 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

On March 26, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma plc. (the “Company”) that she will not stand for re-election as a Director of the Board of Directors (the “Board”) of the Company at the Company’s 2026 annual general meeti...

19 Mar 2026 8-K: Results of Operations and Financial Condition

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing

17 Feb 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a letter (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its American D...

12 Jan 2026 8-K: Regulation FD Disclosure; Other Events

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program

29 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC)

10 Nov 2025 8-K: Results of Operations and Financial Condition

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025

12 Aug 2025 8-K: Results of Operations and Financial Condition

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025

10 Jul 2025 8-K: Other Events

On July 9, 2025, Mereo BioPharma Group plc (“Mereo” or the “Company”) and Ultragenyx Pharmaceutical Inc. (“Ultragenyx”) announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in...

14 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 13, 2025, Mereo BioPharma Group plc (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed (except for Resolution 6, as further described below). Of the ordina...

13 May 2025 8-K: Results of Operations and Financial Condition

Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)

26 Mar 2025 8-K: Results of Operations and Financial Condition

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025

13 Jan 2025 8-K: Regulation FD Disclosure

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025

12 Nov 2024 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

Setrusumab receives Breakthrough Therapy designation from the FDA

13 Aug 2024 8-K: Results of Operations and Financial Condition

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support